A Study of Tadalafil for Duchenne Muscular Dystrophy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01865084 |
Recruitment Status :
Terminated
(The study is being terminated for lack of efficacy)
First Posted : May 30, 2013
Results First Posted : March 1, 2017
Last Update Posted : October 9, 2019
|
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Muscular Dystrophy, Duchenne |
Interventions |
Drug: Tadalafil Drug: Placebo |
Enrollment | 331 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil |
---|---|---|---|
Arm/Group Description | Placebo taken orally once daily. | 0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily. | 0.6 mg/kg tadalafil taken orally once daily. |
Period Title: Double Blind Period (DB) | |||
Started | 116 | 102 | 113 |
Received at Least One Dose of Study Drug | 116 | 102 | 112 |
Completed | 111 | 98 [1] | 107 |
Not Completed | 5 | 4 | 6 |
Reason Not Completed | |||
Adverse Event | 2 | 2 | 1 |
Protocol Violation | 0 | 0 | 1 |
Withdrawal by Parent/Guardian | 2 | 2 | 4 |
Withdrawal by Subject | 1 | 0 | 0 |
[1]
One participant stopped therapy during the DB period but remained in the study for follow-up.
|
|||
Period Title: Open Label Extension (OLE) Period | |||
Started | 0 [1] | 150 [1] | 165 [1] |
Completed | 0 | 139 | 158 |
Not Completed | 0 | 11 | 7 |
Reason Not Completed | |||
Adverse Event | 0 | 0 | 1 |
Lack of Efficacy | 0 | 0 | 2 |
Lost to Follow-up | 0 | 1 | 0 |
Withdrawal by Parent/Guardian | 0 | 8 | 2 |
Withdrawal by Subject | 0 | 2 | 2 |
[1]
Participants who were on Placebo during the double blind period were assigned tadalafil during OLE.
|
Baseline Characteristics
Arm/Group Title | Placebo | 0.3 mg/kg Tadalafil | 0.6 mg/kg Tadalafil | Total | |
---|---|---|---|---|---|
Arm/Group Description | Placebo taken orally once daily. | 0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily. | 0.6 mg/kg tadalafil taken orally once daily. | Total of all reporting groups | |
Overall Number of Baseline Participants | 116 | 102 | 113 | 331 | |
Baseline Analysis Population Description |
All participants who were randomized to study drug.
|
||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
|||||
Number Analyzed | 116 participants | 102 participants | 113 participants | 331 participants | |
9.4 (1.76) | 9.9 (2.26) | 9.5 (1.71) | 9.6 (1.92) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 116 participants | 102 participants | 113 participants | 331 participants | |
Female |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Male |
116 100.0%
|
102 100.0%
|
113 100.0%
|
331 100.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 116 participants | 102 participants | 113 participants | 331 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
2 1.8%
|
2 0.6%
|
|
Asian |
15 12.9%
|
16 15.7%
|
20 17.7%
|
51 15.4%
|
|
Native Hawaiian or Other Pacific Islander |
3 2.6%
|
1 1.0%
|
3 2.7%
|
7 2.1%
|
|
Black or African American |
0 0.0%
|
0 0.0%
|
1 0.9%
|
1 0.3%
|
|
White |
96 82.8%
|
82 80.4%
|
84 74.3%
|
262 79.2%
|
|
More than one race |
2 1.7%
|
3 2.9%
|
2 1.8%
|
7 2.1%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
1 0.9%
|
1 0.3%
|
|
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 116 participants | 102 participants | 113 participants | 331 participants |
Argentina |
7 6.0%
|
4 3.9%
|
6 5.3%
|
17 5.1%
|
|
Russian Federation |
4 3.4%
|
4 3.9%
|
4 3.5%
|
12 3.6%
|
|
United States |
39 33.6%
|
34 33.3%
|
34 30.1%
|
107 32.3%
|
|
Japan |
6 5.2%
|
5 4.9%
|
6 5.3%
|
17 5.1%
|
|
Spain |
9 7.8%
|
7 6.9%
|
12 10.6%
|
28 8.5%
|
|
Canada |
8 6.9%
|
7 6.9%
|
8 7.1%
|
23 6.9%
|
|
Netherlands |
2 1.7%
|
1 1.0%
|
3 2.7%
|
6 1.8%
|
|
Turkey |
5 4.3%
|
7 6.9%
|
8 7.1%
|
20 6.0%
|
|
Belgium |
8 6.9%
|
5 4.9%
|
4 3.5%
|
17 5.1%
|
|
Taiwan |
6 5.2%
|
4 3.9%
|
8 7.1%
|
18 5.4%
|
|
Korea, Republic of |
3 2.6%
|
4 3.9%
|
5 4.4%
|
12 3.6%
|
|
Italy |
8 6.9%
|
8 7.8%
|
8 7.1%
|
24 7.3%
|
|
France |
3 2.6%
|
2 2.0%
|
2 1.8%
|
7 2.1%
|
|
Germany |
8 6.9%
|
10 9.8%
|
5 4.4%
|
23 6.9%
|
Outcome Measures
Adverse Events
Limitations and Caveats
The Sponsor concluded that the efficacy results do not provide sufficient justification for continuance of the open-label extension (OLE) period of the study, where all participants were receiving daily treatment with tadalafil.
More Information
Results Point of Contact
Name/Title: | Chief Medical Officer |
Organization: | Eli Lilly and Company |
Phone: | 800-545-5979 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT01865084 |
Other Study ID Numbers: |
15122 H6D-MC-LVJJ ( Other Identifier: Eli Lilly and Company ) |
First Submitted: | May 24, 2013 |
First Posted: | May 30, 2013 |
Results First Submitted: | September 30, 2016 |
Results First Posted: | March 1, 2017 |
Last Update Posted: | October 9, 2019 |